TY  - GEN
AU  - Cassinello, J.
AU  - Climent, M. A.
AU  - Gonzalez Del Alba, Aranzazu
AU  - Mellado, B.
AU  - Virizuela, J. A.
PY  - 2014
DO  - 10.1007/s12094-014-1225-3
SN  - 1699-048X
UR  - http://hdl.handle.net/20.500.12105/20025
AB  - Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since...
LA  - eng
PB  - Springer
KW  - Androgen deprivation treatment
KW  - Castration-resistant prostate cancer
KW  - Docetaxel
KW  - Cabacitaxel
KW  - Abiraterone
KW  - Enzalutamide
KW  - Radium 223
KW  - Male
KW  - Adenocarcinoma
KW  - Humans
KW  - Prostatic Neoplasms
KW  - Antineoplastic Agents
TI  - SEOM Clinical guidelines for the treatment of metastatic prostate cancer
TY  - research article
ER  -